Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...

When it comes to viral production, researchers are faced with a plethora of variables and decisions. From viral vector type and cell culture format to transfection parameters, knowing how to set up a ...

A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...

VintaBio is a viral vector manufacturing technology company delivering its proprietary innovations through end-to-end CMO services. At the core of its offering is VintaProcess, an intensified adherent ...

The overall process for developing and manufacturing vaccines and cell and gene therapies (CGTs) is challenging and resource intensive because it involves complex and variable raw materials, demanding ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Transfection alters the genetic makeup of eukaryotic cells by introducing foreign nucleic acids, including DNA, RNA, and small noncoding RNAs such as siRNA, shRNA, and miRNA. Scientists use ...

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...